组织激肽释放酶基因多态性A1789G对高血压患者血浆肌酐水平的影响

中国临床药理学与治疗学 ›› 2005, Vol. 10 ›› Issue (6): 637-641.

组织激肽释放酶基因多态性A1789G对高血压患者血浆肌酐水平的影响

洪宗元, 张秀清¹, 黄帼¹, 凌代俊¹, 徐希平¹

皖南医学院药理学教研室, 芜湖241001, 安徽;¹中国科学技术大学生命科学学院, 合肥230027, 安徽

收稿日期:2005-04-07 修回日期:2005-06-20 出版日期:2005-06-26 发布日期:2020-11-12
通讯作者: HONG Zong-yuan, male, associate professor, PhD., engaged in pharmacogenetics and neuropharmacology. Tel:0553-5875499 E-mail: zyhongwnmc@yahoo.com.cn
基金资助:
The experimental work was finished in University of Science and Technology of China.

Effects of human tissue kallikrein gene A1789G polymorphism on plasma creatinine levels in patients with essential hypertension

HONG Zong-yuan, ZHANG Xiu-qing¹, HUANG Guo¹, LING Dai-jun¹, XU Xi-ping¹

Department of Pharmacology, Wannan Medical College, Wuhu 241001, Anhui, China; ¹School of Life Science, University of Science and Technology of China (USTC), Hefei 230027, Anhui, China

Received:2005-04-07 Revised:2005-06-20 Online:2005-06-26 Published:2020-11-12

摘要/Abstract

摘要： 目的: 探讨组织激肽释放酶基因多态性对高血压患者血浆肌酐水平的影响。方法: 用聚合酶链反应—限制性片段长度多态性(PCR-RFLP) 方法对733 例高血压患者的组织激肽释放酶基因A1789G多态位点进行基因分型, 用线性回归模型分析基因型与血浆肌酐水平之间的关系, 用方差分析分析基因型和血压对血浆肌酐水平的交互影响。结果: 携带突变型等位基因1789G(基因型AG 或GG) 高血压患者较携带野生型等位基因A1789(基因型AA) 患者的血浆肌酐水平明显升高, 且血浆肌酐水平随着血压的升高而升高。结论: 组织激肽释放酶基因多态性对高血压患者的血浆肌酐水平产生明显影响,A1789G 多态位点是高血压患者血浆肌酐清除率下降的一个危险因素。

关键词: 组织激肽释放酶, 基因多态性, 血浆肌酐, 高血压, PCR-限制性片段长度多态性

Abstract: AIM: To investigate the effect of the human tissue kallikrein gene (hKLK1) polymorphism on plasma creatinine levels in hypertensive subjects. METHODS: The hKLK1 A1789G polymorphism was genotyped by PCR-restriction fragment length polymorphism (RFLP) in 733 hypertensive subjects. The relationship between genotype and plasma creatinine level was performed by a multiple regression analysis. The interactive effect of genotype and blood pressure on the plasma creatinine level was accessed by ANOVA. RESULTS: Multiple regression analysis showed that the plasma creatinine level was significantly higher in the subjects with mutant allele G (AG or GG genotype) than in those with wild allele A (AA genotype) (P =0.009 and P = 0.046, respectively). ANOVA indicated that the AG and GG genotype individuals had high plasma creatinine levels in SBP and DBP Compared with AA genotype individuals, and the plasma creatinine level increased with blood pressure rises (P <0.05). CONCLUSION: The hKLK1 A1789G polymorphism influences plasma creatinine level, and the A1789→G variation is a risk factor in renal plasma creatinine clearance rate decline in hypertensive individuals.

Key words: tissue kallikrein, gene polymorphism, plasma creatinine, hypertension, PCR-RFLP

中图分类号:

R966

洪宗元, 张秀清, 黄帼, 凌代俊, 徐希平. 组织激肽释放酶基因多态性A1789G对高血压患者血浆肌酐水平的影响[J]. 中国临床药理学与治疗学, 2005, 10(6): 637-641.

HONG Zong-yuan, ZHANG Xiu-qing, HUANG Guo, LING Dai-jun, XU Xi-ping. Effects of human tissue kallikrein gene A1789G polymorphism on plasma creatinine levels in patients with essential hypertension[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(6): 637-641.

参考文献

1 Meneton P, Bloch-Faure M, Hagege AA, Ruetten H, Huang W, Bergaya S, et al.Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice[J]. Proc Natl Acad Sci U S A, 2001;98: 2634-9
2 Xiong W, Chao J, Chao L.Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats[J]. Hypertension, 1995;25: 715-9
3 Bhoola KD, Figueroa CD, Worthy K.Bioregulation of kinins: kallikreins, kininogens and kininases [J]. Pharmacol Rev, 1992;44:1-80
4 Yu H, Song Q, Freedman BI, Chao J, Chao L, Rich SS, et al.Association of the tissue kallikrein gene promoter with ESRD and hypertension[J]. Kidney Int, 2002; 61:1030-9
5 Elliot R, Nuzum FR. Urinary excretion of a depressor substance (kallikrein of frey and kraut) in arterial hypertension[J]. Endocrinology, 1934; 18:462-74
6 Carretero OA, Polomski C, Hampton A, Scicli AG. Urinary kallikrein, plasma renin and aldosterone in New Zealand genetically hypertensive (GH) rats[J]. Clin Exp Pharmacol Physiol, 1976;3:55-9
7 Carretero OA, Amin VM, Ocholik T, Scicli AG, Koch J. Urinary kallikrein in rats bred for their susceptibility and resistance to the hypertensive effect of salt. A new radioimmunoassay for its direct determination[J]. Circ Res, 1978;42:727-31
8 Ader JL, Tran-Van T, Praddaude F.Low urinary excretion of active and total kallikrein in developing spontaneously hypertensiverats and effect of long term converting enzyme inhibition[J]. Agents Actions Suppl, 1987; 22:329-38
9 Ader JL, Tran-Van T, Praddaude F.Renal tissue kallikrein in newborn and young SHR[J]. Am J Hypertens, 1987; 1: S53-5
10 Williams RR, Hunt SC, Wu LL, Hasstedt ST, Barlow GK, Stults BM, et al. Early pathogenesis of primary hypertension: biological markers of genetically predisposed hypertension[M]. Amsterdam:Elsevier Science Publishing, 1987
11 Wolf WC, Harley RA, Sluce D, Chao L, Chao J.Localization and expression of tissue kallikrein and kallistatin in human blood vessels[J]. J Histochem Cytochem, 1999;47: 221-8
12 Margolis HS, Geller R, Pisano JJ, Sjoerdsma A.Altered urinary kallikrein excretion in human hypertension[J]. Lancet; 1971; 2:1063-5
13 Zinner SH, Margolius HS, Rosner B, Kass EH.Stability of blood pressure rank and urinary kallikrein concentration in childhood:an eight-year follow-up[J]. Circulation, 1978;58: 908-15
14 Overlack A, Stumpe KO, Kolloch R, Ressel C, Krueck F. Antihypertensive effect of orally administered glandular kallikrein in essential hypertension.Results of double blind study [J]. Hypertension, 1981;3: I18-21
15 Ogawa K, Ito T, Ban M, Mochizuki M, Satake T.Effects of orally administered glandular kallikrein on urinary kallikrein and prostaglandin excretion, plasma immunoreactive prostanoids and platelet aggregation in essential hypertension[J]. KlinWochenschr, 1985; 63:332-6
16 Pravence M, Ken V, Kunes J, Carretero OA, Simonet L, Kurtz TW.Cosegregation of blood pressure with a kallikrein gene family polymorphism[J]. Hypertension, 1991;17:242-6
17 Woodley-Miller C, Chao J, Chao L.Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes[J]. J Hypertens, 1989;7: 865-71
18 Wang J, Xiong W, Yang Z, Davis T, Dewey MJ, Chao J, et al.Human tissue kallikrein induces hypotension in transgenic mice[J]. Hypertension, 1994; 23:236-43
19 Berry TD, Hasstedt SJ, Hunt SC, Wu LL, Smith JB, Ash O, et al.A gene for high urinary kallikrein may protect against hypertension in Utah kindreds[J]. Hypertension, 1989; 13:3-8
20 Slim R, Torremocha F, Moreau T, Pizard A, Hunt SC, Vuagnat A, et al.Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity[J]. J Am Soc Nephrol, 2002;13:968-76
21 Berge KE, Bakken A, Bohn M, Erikssen J, Berg K.Analy ses of mutations in the human renal kallikrein (hKLK1) gene and their possible relevance to blood pressure regulation and risk of myocardial infarction[J]. Clin Genet, 1997;52:86-95
22 Evans BA, Yun ZX, Close JA, Tregear GW, Kitamura N, Nakanishi S, et al.Structure and chromosomal localization of the human renal kallikrein gene[J]. Biochemistry, 1988; 27: 3124-9
23 Granger JP, Hall JE.Acute and chronic actions of bradykinin on renal function and arterial pressure[J]. Am J Physiol, 1985;248:F87-92

[1]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[2]	朱丽, 魏兵, 廖世峨, 张超, 郑晓宇, 刘亚军. 药物代谢酶细胞色素P450单核苷酸多态性影响哮喘儿童吸入皮质醇激素疗效研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 536-543.
[3]	张志英, 靳秀红, 张小宁, 张向峰, 罗青林, 张松林. TBX21和ADCY9多态性在儿童哮喘发生发展中的临床研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 407-412.
[4]	宁思思, 赵玉红, 颜蕾, 唐敏娜, 张凝之, 张泳巧, 崔兆强. 高血压合并慢性肾脏病患者的降压目标之争议[J]. 中国临床药理学与治疗学, 2023, 28(4): 463-467.
[5]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[6]	王爽, 刘嘉, 张月丽. POR*28基因多态性与中国肾移植患者他克莫司稳定剂量的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(9): 991-997.
[7]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.
[8]	陈文刚, 殷勤, 张巍巍, 周露露, 寇婉青, 袁小龙. 皖南地区高血压患者MTHFR基因多态性分布及与血Hcy相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 768-774.
[9]	武元竹, 刘俊, 杨魁, 彭静, 栾家杰, 韦俊, 张大发, 宋帅, 袁小龙, 王中方, 张年宝, 解丹, 姜鹏, 范洁. 安徽地区汉族人群CYP2C9*3和VKORC1-1639G>A基因多态性分布及对华法林稳定剂量的影响[J]. 中国临床药理学与治疗学, 2022, 27(6): 652-659.
[10]	张凝之, 赵玉红, 唐敏娜, 张泳巧, 宁思思, 崔兆强. 时辰药理学在高血压治疗中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 418-422.
[11]	崔素梅, 崔兆强. β受体阻滞剂与高血压治疗[J]. 中国临床药理学与治疗学, 2022, 27(4): 423-427.
[12]	李远方, 崔兆强. 高血压合并高尿酸血症的应对之策[J]. 中国临床药理学与治疗学, 2022, 27(4): 428-432.
[13]	徐建飞, 林利. 高血压药物治疗与非药物治疗研究进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 433-441.
[14]	蒯铮, 张潇伊, 邹云增. 血管紧张素受体脑啡肽酶抑制剂在老年高血压中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 442-445.
[15]	刘桂剑, 程宽, 朱文青, 葛均波. 高血压的药物治疗进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 446-449.